WithdrawnPhase 2NCT04274166

Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum

Studying Classic pyoderma gangrenosum

Last synced from ClinicalTrials.gov May 6, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Wake Forest University Health Sciences
Principal Investigator: William W Huang, MD. MPH
Wake Forest University Health Sciences
Intervention: secukinumab 150 mg (2 injections per dose(drug)
Eligibility: 18-75 years · All sexes
Timeline: 2021 – 2022

Collaborators

Novartis

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04274166 on ClinicalTrials.gov

Other trials for Classic pyoderma gangrenosum

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE3NCT06624670
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
Boehringer Ingelheim
RECRUITINGPHASE2NCT06563323
Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)
Oregon Health and Science University

See all trials for Classic pyoderma gangrenosum →

← Back to all trials